Cargando…

Inflammatory Bowel Diseases and Parkinson’s Disease

The etiology of Parkinson’s disease (PD) is multifactorial, with genetics, aging, and environmental agents all a part of the PD pathogenesis. Widespread aggregation of the α-synuclein protein in the form of Lewy bodies and Lewy neurites, and degeneration of substantia nigra dopamine neurons are the...

Descripción completa

Detalles Bibliográficos
Autor principal: Brudek, Tomasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839501/
https://www.ncbi.nlm.nih.gov/pubmed/31609699
http://dx.doi.org/10.3233/JPD-191729
_version_ 1783467436144590848
author Brudek, Tomasz
author_facet Brudek, Tomasz
author_sort Brudek, Tomasz
collection PubMed
description The etiology of Parkinson’s disease (PD) is multifactorial, with genetics, aging, and environmental agents all a part of the PD pathogenesis. Widespread aggregation of the α-synuclein protein in the form of Lewy bodies and Lewy neurites, and degeneration of substantia nigra dopamine neurons are the pathological hallmarks of PD. Inflammatory responses manifested by glial reactions, T cell infiltration, and increased expression of inflammatory cytokines, as well as other toxic mediators derived from activated glial cells, are currently recognized as prominent features of PD. Experimental, clinical and epidemiological data suggest that intestinal inflammation contributes to the pathogenesis of PD, and the increasing number of studies suggests that the condition may start in the gastrointestinal system years before any motor symptoms develop. Patients with inflammatory bowel disease (IBD) have a higher risk of developing PD compared with non-IBD individuals. Gene association study has found a genetic link between IBD and PD, and an evidence from animal studies suggests that gut inflammation, similar to that observed in IBD, may induce loss of dopaminergic neurons. Based on preclinical models of PD, it is suggested that the enteric microbiome changes early in PD, and gut infections trigger α-synuclein release and aggregation. In this paper, the possible link between IBD and PD is reviewed based on the available literature. Given the potentially critical role of gastrointestinal pathology in PD pathogenesis, there is reason to suspect that IBD or its treatments may impact PD risk. Thus, clinicians should be aware of PD symptoms in IBD patients.
format Online
Article
Text
id pubmed-6839501
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-68395012019-11-20 Inflammatory Bowel Diseases and Parkinson’s Disease Brudek, Tomasz J Parkinsons Dis Review The etiology of Parkinson’s disease (PD) is multifactorial, with genetics, aging, and environmental agents all a part of the PD pathogenesis. Widespread aggregation of the α-synuclein protein in the form of Lewy bodies and Lewy neurites, and degeneration of substantia nigra dopamine neurons are the pathological hallmarks of PD. Inflammatory responses manifested by glial reactions, T cell infiltration, and increased expression of inflammatory cytokines, as well as other toxic mediators derived from activated glial cells, are currently recognized as prominent features of PD. Experimental, clinical and epidemiological data suggest that intestinal inflammation contributes to the pathogenesis of PD, and the increasing number of studies suggests that the condition may start in the gastrointestinal system years before any motor symptoms develop. Patients with inflammatory bowel disease (IBD) have a higher risk of developing PD compared with non-IBD individuals. Gene association study has found a genetic link between IBD and PD, and an evidence from animal studies suggests that gut inflammation, similar to that observed in IBD, may induce loss of dopaminergic neurons. Based on preclinical models of PD, it is suggested that the enteric microbiome changes early in PD, and gut infections trigger α-synuclein release and aggregation. In this paper, the possible link between IBD and PD is reviewed based on the available literature. Given the potentially critical role of gastrointestinal pathology in PD pathogenesis, there is reason to suspect that IBD or its treatments may impact PD risk. Thus, clinicians should be aware of PD symptoms in IBD patients. IOS Press 2019-10-30 /pmc/articles/PMC6839501/ /pubmed/31609699 http://dx.doi.org/10.3233/JPD-191729 Text en © 2019 – IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Brudek, Tomasz
Inflammatory Bowel Diseases and Parkinson’s Disease
title Inflammatory Bowel Diseases and Parkinson’s Disease
title_full Inflammatory Bowel Diseases and Parkinson’s Disease
title_fullStr Inflammatory Bowel Diseases and Parkinson’s Disease
title_full_unstemmed Inflammatory Bowel Diseases and Parkinson’s Disease
title_short Inflammatory Bowel Diseases and Parkinson’s Disease
title_sort inflammatory bowel diseases and parkinson’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839501/
https://www.ncbi.nlm.nih.gov/pubmed/31609699
http://dx.doi.org/10.3233/JPD-191729
work_keys_str_mv AT brudektomasz inflammatoryboweldiseasesandparkinsonsdisease